Cutanos
Cutanos GmbH is a Vienna-based biotechnology company developing a ligand‑based delivery platform that targets Langerhans cells in skin for antigen delivery. The platform functionalizes lipid nanoparticles or liposomes with glycomimetic ligands selective for the Langerin receptor to achieve cell-specific mRNA and protein antigen delivery, enabling transdermal administration via microneedles or microinjectors, preclinical dose-sparing and enhanced immune responses, and partnerships for therapeutic applications.
Industries
Nr. of Employees
small (1-50)
Products
Langerhans cell-targeted delivery platform (LC-TDS)
A modular delivery platform that functionalizes lipid nanoparticles or liposomes with glycomimetic ligands selective for Langerhans cells to deliver mRNA or protein antigens via skin administration.
LC-TDS
A first-of-a-kind targeted delivery platform designed to direct LNP formulations and mRNA directly to Langerhans cells in the skin via minimally invasive microneedles or microinjectors.
Langerhans cell-targeted delivery platform (LC-TDS)
A modular delivery platform that functionalizes lipid nanoparticles or liposomes with glycomimetic ligands selective for Langerhans cells to deliver mRNA or protein antigens via skin administration.
LC-TDS
A first-of-a-kind targeted delivery platform designed to direct LNP formulations and mRNA directly to Langerhans cells in the skin via minimally invasive microneedles or microinjectors.
Services
Partnerships and funded collaborative research to adapt cell-targeted delivery approaches for therapeutic applications.
Preclinical testing of targeted nanoparticle formulations in murine models and primary human skin cell assays.
Partnerships and funded collaborative research to adapt cell-targeted delivery approaches for therapeutic applications.
Preclinical testing of targeted nanoparticle formulations in murine models and primary human skin cell assays.
Expertise Areas
- Cell-targeted vaccine delivery
- Transdermal delivery systems
- mRNA delivery and formulation
- Protein antigen delivery
Key Technologies
- Lipid nanoparticle (LNP) formulation
- Liposomal delivery
- Ligand-mediated cell targeting
- Glycomimetic ligand synthesis
News & Updates
Awarded first place in the BARDA VITAL Prize Challenge for an innovative vaccine technology (USD 20,000 prize).
Appointment of interim Managing Director (leadership transition announced).
Langerhans Cell-targeted mRNA Delivery: A Strategy for Dose-Sparing and Enhanced Anti-Tumor Immunity
Preprint reporting selective mRNA delivery to murine and human Langerhans cells with increased mRNA translation, enhanced antigen presentation, dose-sparing and improved anti-tumor immunity in a B16-OVA model.
Preprint describing targeted protein antigen delivery to Langerhans cells using a glycomimetic ligand, resulting in increased antigen-specific T cell expansion and activation in vivo.
Peer-reviewed publication describing a glycomimetic ligand selective for human Langerhans cell targeting (ACS Central Science, 2019).
Peer-reviewed publication on targeted protein antigen delivery to human Langerhans cells (Frontiers in Immunology, 2021).
Awarded first place in the BARDA VITAL Prize Challenge for an innovative vaccine technology (USD 20,000 prize).
Appointment of interim Managing Director (leadership transition announced).
Langerhans Cell-targeted mRNA Delivery: A Strategy for Dose-Sparing and Enhanced Anti-Tumor Immunity
Preprint reporting selective mRNA delivery to murine and human Langerhans cells with increased mRNA translation, enhanced antigen presentation, dose-sparing and improved anti-tumor immunity in a B16-OVA model.
Preprint describing targeted protein antigen delivery to Langerhans cells using a glycomimetic ligand, resulting in increased antigen-specific T cell expansion and activation in vivo.
Peer-reviewed publication describing a glycomimetic ligand selective for human Langerhans cell targeting (ACS Central Science, 2019).
Peer-reviewed publication on targeted protein antigen delivery to human Langerhans cells (Frontiers in Immunology, 2021).